Alkem Laboratories (NSE:ALKEM) EBIT: ₹30,317 Mil (TTM As of Mar. 2026)


NSE:ALKEM Alkem Laboratories Ltd NSE:ALKEM
96 GF Score
Price ₹5,425.00
GF Value ₹6,066.47
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alkem Laboratories EBIT?

Alkem Laboratories NSE:ALKEM -0.06% 96 EBIT is ₹30,317 Mil as of Mar. 2026. GuruFocus rates NSE:ALKEM with a GF Score™ of 96/100 and a GF Value™ of ₹6,066.47 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Alkem Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹4,767 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹30,317 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alkem Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 7.22%. Alkem Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 27.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alkem Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.85%.

Alkem Laboratories  (NSE:ALKEM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alkem Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=16465.2 * ( 1 - 40.48% )/( (0 + 135695.2)/ 1 )
=9800.08704/135695.2
=7.22 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=208729.7 - 23107.2 - ( 49927.3 - max(0, 47827 - 122105.2+49927.3))
=135695.2

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Alkem Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=19069.2/( ( (0 + max(0, 0)) + (32285.4 + max(36063.9, 0)) )/ 1 )
=19069.2/( ( 0 + 68349.3 )/ 1 )
=19069.2/68349.3
=27.90 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29791.1 + 33332.2 + 8988.3) - (23107.2 + 0 + 12940.5)
=36063.9

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alkem Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=30316.7/624472.725
=4.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkem Laboratories EBIT Related Terms

Alkem Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Alkem Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkem Laboratories EBIT Chart

Alkem Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,851.20 13,985.20 21,188.40 26,487.30 30,316.70

Alkem Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,247.60 8,007.90 9,308.50 8,233.00 4,767.30

NSE:ALKEM vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkem Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's EV-to-EBIT falls into.


NSE:ALKEM
96GF Score
Alkem Laboratories Ltd NSE:ALKEM
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkem Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30,317 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹30,317 Mil mean?
Alkem Laboratories (NSE:ALKEM) has a EBIT of ₹30,317 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Alkem Laboratories.
Is Alkem Laboratories' EBIT too high?
Alkem Laboratories' current EBIT is ₹30,317 Mil. Overall, Alkem Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' EBIT compare to ZTS?
Alkem Laboratories' EBIT of ₹30,317 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Alkem Laboratories. Alkem Laboratories's current EBIT is ₹30,317 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,066.47, compared to a current price of ₹5,425.00 — trading 10.6% below its estimated fair value. The current EBIT is ₹30,317 Mil. Alkem Laboratories' overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current EBIT is ₹30,317 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?

Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued. The current stock price of ₹5,425.00 is trading 10.6% below its estimated GF Value™ of ₹6,066.47. GuruFocus considers Alkem Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:ALKEM:

  • EBIT: ₹30,317 Mil
  • GF Value™: ₹6,066.47 vs. price of ₹5,425.00 (10.6% below fair value)
  • GF Score™: 96/100 with 1 warning sign

No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkem Laboratories Business Description

Other Exchanges 539523:India
Address Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
96GF Score

Get the complete analysis for NSE:ALKEM

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5,425.00
Price
₹6,066.47
GF Value